SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer

Cancer Cell

Volumn 25, Issue 4, 2014, Pages 455-468

  Li, Guoqiang ^a,b   Ci, Weimin ^a   Karmakar, Subhradip ^c,d   Chen, Ke ^a   Dhar, Ruby ^c,d   Fan, Zhixiang ^g   Guo, Zhongqiang ^a,h   Zhang, Jing ^a   Ke, Yuwen ^a   Wang, Lu ^a,b   Zhuang, Min ^j   Hu, Shengdi ^k   Li, Xuesong ^h   Zhou, Liqun ^h   Li, Xianghong ⁱ   Calabrese, Matthew F ^l   Watson, Edmond R ^l   Prasad, SandipM ^a   Rinker Schaeffer, Carrie ^d   Eggener, ScottE ^d   Stricker, Thomas ^c,f   Tian, Yong ^k   Schulman, Brenda A ^l   Liu, Jiang ^a   White, Kevin P ^c,d,e   more..

^a Chinese Academy of Sciences and China National Center for Bioinformation   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g KUNMING MEDICAL UNIVERSITY   (China)

^h PEKING UNIVERSITY FIRST HOSPITAL   (China)

ⁱ PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k INSTITUTE OF BIOPHYSICS   (China)

^l ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DAXX PROTEIN; NUCLEAR PROTEIN; PHOSPHATASE; PROTEIN; REGULATOR PROTEIN; SPECKLE TYPE POZ PROTEIN; TRANSCRIPTION FACTOR GLI2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR GROWTH; UBIQUITINATION;

ERINACEIDAE;

ANIMALS; CARCINOGENESIS; CARCINOMA, RENAL CELL; CELL TRANSFORMATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HETEROGRAFTS; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NUCLEAR PROTEINS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84898539268     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.02.007     Document Type: Article

References (65)

1. Arimoto K., Fukuda H., Imajoh-Ohmi S., Saito H., Takekawa M. Formation of stress granules inhibits apoptosis by suppressing stress-responsive MAPK pathways. Nat. Cell Biol. 2008, 10:1324-1332.
2. Berger M.F., Lawrence M.S., Demichelis F., Drier Y., Cibulskis K., Sivachenko A.Y., Sboner A., Esgueva R., Pflueger D., Sougnez C., et al. The genomic complexity of primary human prostate cancer. Nature 2011, 470:214-220.
3. Bhatia B., Hsieh M., Kenney A.M., Nahlé Z. Mitogenic Sonic hedgehog signaling drives E2F1-dependent lipogenesis in progenitor cells and medulloblastoma. Oncogene 2011, 30:410-422.
4. Brenner W., Färber G., Herget T., Lehr H.A., Hengstler J.G., Thüroff J.W. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int. J. Cancer 2002, 99:53-57.
5. Brugarolas J. Renal-cell carcinoma-molecular pathways and therapies. N.Engl. J. Med. 2007, 356:185-187.
6. Bunce M.W., Boronenkov I.V., Anderson R.A. Coordinated activation of the nuclear ubiquitin ligase Cul3-SPOP by the generation of phosphatidylinositol 5-phosphate. J.Biol. Chem. 2008, 283:8678-8686.
7. Campbell L., Nuttall R., Griffiths D., Gumbleton M. Activated extracellular signal-regulated kinase is an independent prognostic factor in clinically confined renal cell carcinoma. Cancer 2009, 115:3457-3467.
8. Comprehensive molecularcharacterization of clear cell renal cell carcinoma. Nature 2013, 499:43-49. Cancer Genome Atlas Research Network.
9. Cen L., Arnoczky K.J., Hsieh F.-C., Lin H.-J., Qualman S.J., Yu S., Xiang H., Lin J. Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma. Mod. Pathol. 2007, 20:936-946.
10. Chi J.-T., Wang Z., Nuyten D.S.A., Rodriguez E.H., Schaner M.E., Salim A., Wang Y., Kristensen G.B., Helland Å., Børresen-Dale A.-L., et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 2006, 3:e47.
11. Dhillon A.S., Hagan S., Rath O., Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007, 26:3279-3290.
12. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., Negrier S., Chevreau C., Solska E., Desai A.A., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N.Engl. J. Med. 2007, 356:125-134. TARGET Study Group.
13. Fyfe G.A., Fisher R.I., Rosenberg S.A., Sznol M., Parkinson D.R., Louie A.C. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J.Clin. Oncol. 1996, 14:2410-2411.
14. Gardai S.J., Whitlock B.B., Xiao Y.Q., Bratton D.B., Henson P.M. Oxidants inhibit ERK/MAPK and prevent its ability to delay neutrophil apoptosis downstream of mitochondrial changes and at the level of XIAP. J.Biol. Chem. 2004, 279:44695-44703.
15. Gottfried Y., Rotem A., Lotan R., Steller H., Larisch S. The mitochondrial ARTS protein promotes apoptosis through targeting XIAP. EMBO J. 2004, 23:1627-1635.
16. Hamid T., Malik M.T., Kakar S.S. Ectopic expression of PTTG1/securin promotes tumorigenesis in human embryonic kidney cells. Mol. Cancer 2005, 4:3.
17. Hernández-Muñoz I., Lund A.H., van der Stoop P., Boutsma E., Muijrers I., Verhoeven E., Nusinow D.A., Panning B., Marahrens Y., van Lohuizen M. Stable X chromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase. Proc. Natl. Acad. Sci. USA 2005, 102:7635-7640.
18. Hollander M.C., Blumenthal G.M., Dennis P.A. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat. Rev. Cancer 2011, 11:289-301.
19. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermott D., Bodrogi I., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N.Engl. J. Med. 2007, 356:2271-2281. Global ARCC Trial.
20. Hung M.-C., Link W. Protein localization in disease and therapy. J.Cell Sci. 2011, 124:3381-3392.
21. Jiang Y., Zhang W., Kondo K., Klco J.M., St Martin T.B., Dufault M.R., Madden S.L., Kaelin W.G., Nacht M. Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. Mol. Cancer Res. 2003, 1:453-462.
22. Kaelin W.G. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2002, 2:673-682.
23. Kaelin W.G. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat. Rev. Cancer 2008, 8:865-873.
24. Kapoor A., Figlin R.A. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer 2009, 115:3618-3630.
25. Kass E.M., Ahn J., Tanaka T., Freed-Pastor W.A., Keezer S., Prives C. Stability of checkpoint kinase 2 is regulated via phosphorylation at serine 456. J.Biol. Chem. 2007, 282:30311-30321.
26. Kent D., Bush E.W., Hooper J.E. Roadkill attenuates Hedgehog responses through degradation of Cubitus interruptus. Development 2006, 133:2001-2010.
27. Keyse S.M. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 2008, 27:253-261.
28. Kim W.Y., Kaelin W.G. Role of VHL gene mutation in human cancer. J.Clin. Oncol. 2004, 22:4991-5004.
29. Kim J., Kato M., Beachy P.A. Gli2 trafficking links Hedgehog-dependent activation of Smoothened in the primary cilium to transcriptional activation in the nucleus. Proc. Natl. Acad. Sci. USA 2009, 106:21666-21671.
30. Kucejova B., Peña-Llopis S., Yamasaki T., Sivanand S., Tran T.A.T., Alexander S., Wolff N.C., Lotan Y., Xie X.-J., Kabbani W., et al. Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. Mol. Cancer Res. 2011, 9:1255-1265.
31. Kwon J.E., La M., Oh K.H., Oh Y.M., Kim G.R., Seol J.H., Baek S.H., Chiba T., Tanaka K., Bang O.S., et al. BTB domain-containing speckle-type POZ protein (SPOP) serves as an adaptor of Daxx for ubiquitination by Cul3-based ubiquitin ligase. J.Biol. Chem. 2006, 281:12664-12672.
32. Lee J.O., Yang H., Georgescu M.M., Di Cristofano A., Maehama T., Shi Y., Dixon J.E., Pandolfi P., Pavletich N.P. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999, 99:323-334.
33. Lee H.J., Kim D.I., Kang G.H., Kwak C., Ku J.H., Moon K.C. Phosphorylation of ERK1/2 and prognosis of clear cell renal cell carcinoma. Urology 2009, 73:394-399.
34. Li C., Ao J., Fu J., Lee D.F., Xu J., Lonard D., O'Malley B.W. Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. Oncogene 2011, 30:4350-4364.
35. Liu J., Ghanim M., Xue L., Brown C.D., Iossifov I., Angeletti C., Hua S., Nègre N., Ludwig M., Stricker T., et al. Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer. Science 2009, 323:1218-1222.
36. Lopez-Beltran A., Scarpelli M., Montironi R., Kirkali Z. 2004WHO classification of the renal tumors of the adults. Eur. Urol. 2006, 49:798-805.
37. Mains P., Kemphues K., Sprunger S., Sulston I., Wood W. Mutations affecting the meiotic and mitotic divisions of the early Caenorhabditis elegans embryo. Genetics 1990, 126:593-605.
38. McDermott D.F., Regan M.M., Clark J.I., Flaherty L.E., Weiss G.R., Logan T.F., Kirkwood J.M., Gordon M.S., Sosman J.A., Ernstoff M.S., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J.Clin. Oncol. 2005, 23:133-141.
39. Miyazaki K., Kawamoto T., Tanimoto K., Nishiyama M., Honda H., Kato Y. Identification of functional hypoxia response elements in the promoter region of the DEC1 and DEC2 genes. J.Biol. Chem. 2002, 277:47014-47021.
40. Motzer R.J., Molina A.M. Targeting renal cell carcinoma. J.Clin. Oncol. 2009, 27:3274-3276.
41. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S.T., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N.Engl. J. Med. 2007, 356:115-124.
42. Motzer R.J., Escudier B., Tomczak P., Hutson T.E., Michaelson M.D., Negrier S., Oudard S., Gore M.E., Tarazi J., Hariharan S., et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013, 14:552-562.
43. Myers M.P., Pass I., Batty I.H., Van der Kaay J., Stolarov J.P., Hemmings B.A., Wigler M.H., Downes C.P., Tonks N.K. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl. Acad. Sci. USA 1998, 95:13513-13518.
44. Nagai Y., Kojima T., Muro Y., Hachiya T., Nishizawa Y., Wakabayashi T., Hagiwara M. Identification of a novel nuclear speckle-type protein, SPOP. FEBS Lett. 1997, 418:23-26.
45. Nardozzi J.D., Lott K., Cingolani G. Phosphorylation meets nuclear import: a review. Cell Commun. Signal. 2010, 8:32.
46. Negrier S., Escudier B., Lasset C., Douillard J.Y., Savary J., Chevreau C., Ravaud A., Mercatello A., Peny J., Mousseau M., et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N.Engl. J. Med. 1998, 338:1272-1278.
47. Nickerson M.L., Jaeger E., Shi Y., Durocher J.A., Mahurkar S., Zaridze D., Matveev V., Janout V., Kollarova H., Bencko V., et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin. Cancer Res. 2008, 14:4726-4734.
48. Patterson K.I., Brummer T., O'Brien P.M., Daly R.J. Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem. J. 2009, 418:475-489.
49. Pintard L., Willis J.H., Willems A., Johnson J.-L.F., Srayko M., Kurz T., Glaser S., Mains P.E., Tyers M., Bowerman B., et al. The BTB protein MEL-26 is a substrate-specific adaptor of the CUL-3 ubiquitin-ligase. Nature 2003, 425:311-316.
50. Polo J.M., Ci W., Licht J.D., Melnick A. Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells. Blood 2008, 112:644-651.
51. Rini B.I., Campbell S.C., Escudier B. Renal cell carcinoma. Lancet 2009, 373:1119-1132.
52. Robb V.A., Karbowniczek M., Klein-Szanto A.J., Henske E.P. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J.Urol. 2007, 177:346-352.
53. Salomoni P., Khelifi A.F. Daxx: death or survival protein?. Trends Cell Biol. 2006, 16:97-104.
54. Sansal I., Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J.Clin. Oncol. 2004, 22:2954-2963.
55. Sarbassov D.D., Ali S.M., Sabatini D.M. Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 2005, 17:596-603.
56. Sasaki H., Nishizaki Y., Hui C., Nakafuku M., Kondoh H. Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain: implication of Gli2 and Gli3 as primary mediators of Shh signaling. Development 1999, 126:3915-3924.
57. Sato Y., Yoshizato T., Shiraishi Y., Maekawa S., Okuno Y., Kamura T., Shimamura T., Sato-Otsubo A., Nagae G., Suzuki H., et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 2013, 45:860-867.
58. Shinojima T., Oya M., Takayanagi A., Mizuno R., Shimizu N., Murai M. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. Carcinogenesis 2007, 28:529-536.
59. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
60. Wang C., Pan Y., Wang B. Suppressor of fused and Spop regulate the stability, processing and function of Gli2 and Gli3 full-length activators but not their repressors. Development 2010, 137:2001-2009.
61. Wardle E.N. Cyclophosphamide pulse therapy in relapsing nephrotic syndrome. Nephron 1991, 58:377.
62. Wu X., Senechal K., Neshat M.S., Whang Y.E., Sawyers C.L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. USA 1998, 95:15587-15591.
63. Xu L., Wei Y., Reboul J., Vaglio P., Shin T.H., Vidal M., Elledge S.J., Harper J.W. BTB proteins are substrate-specific adaptors inanSCF-like modular ubiquitin ligase containing CUL-3. Nature 2003, 425:316-321.
64. Zhang Q., Zhang L., Wang B., Ou C.Y., Chien C.T., Jiang J. A hedgehog-induced BTB protein modulates hedgehog signaling by degrading Ci/Gli transcription factor. Dev. Cell 2006, 10:719-729.
65. Zhuang M., Calabrese M.F., Liu J., Waddell M.B., Nourse A., Hammel M., Miller D.J., Walden H., Duda D.M., Seyedin S.N., et al. Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. Mol. Cell 2009, 36:39-50.